`seeks partners within
`
`Diabetes
`
`Hemophilia
`and hemostasis
`management
`
`Chronic inflammatory
`and autoimmune
`disorders
`
`Drug delivery and
`protein technologies
`
`Partnering October 2008 / www.novonordisk.com/science/partnering
`
`Novo Nordisk Exhibit 2533
`Mylan Pharms. Inc. v. Novo Nordisk A/S
`IPR2023-00724
`Page 00001
`
`
`
`Novo Nordisk is a focused healthcare company
`
`We are headquartered in Denmark and have affiliates in 80 countries.
`
`Novo Nordisk is a worldwide market leader in diabetes with
`
`• A full portfolio of insulin analogs
`• The broadest portfolio of insulin delivery systems and a leading position
` in the global injection device market.
`
`Novo Nordisk has a leading position in
`
`• Hemophilia with inhibitors
`• Growth hormone disorders
`• Hormone replacement therapy.
`
`Research and Development at Novo Nordisk
`
`We are committed to research and development of new medicines that fulfil unmet
`medical needs and that are aligned with our therapy areas.
`
`Our current research and development pipeline is focused on proteins and peptides
`within:
`
`• Diabetes
`• Hemophilia and hemostasis management
`• Chronic inflammatory and autoimmune disorders.
`
`Collaborations with universities, research institutes, and biotechnology companies
`play a key role in our R&D strategy. Novo Nordisk allocates approximately 20% of its
`research budget to external activities.
`
`Core competence: Proteins from molecule to market
`
`• Protein expression in E.coli, yeast, and mammalian cells on commercial scales
`• Protein engineering by using genetic, enzymatic and chemical modification
` technologies including pegylation and acylation
`• Protein formulation, especially half-life extension, sustained release and liquid
` formulations
`• Protein delivery systems, an area pioneered by Novo Nordisk with the
` introduction of the insulin pen device in 1985. Since then, we have
` developed more than twenty single-use and multi-use injection systems,
` pre-filled and based on cartridges.
`
`Partnering October 2008 / www.novonordisk.com/science/partnering
`
`Novo Nordisk Exhibit 2533
`Mylan Pharms. Inc. v. Novo Nordisk A/S
`IPR2023-00724
`Page 00002
`
`
`
`Novo Nordisk seeks partnerships within
`Diabetes
`
`• Insulins
`• GLP-1s
`• Therapeutic proteins and peptides for:
` •
` Diabetes treatment and prevention
` •
` β-cell regeneration, proliferation or neogenesis
` •
` Obesity treatment.
`
`Hemophilia and hemostasis management
`
`• Prevention and treatment of bleeding in people with hemophilia
`
`• Improvement of rFVIIa therapies for patients with inhibitors,
` including prophylaxis
`
`• Improvement of FVIII and FIX based therapies for patients with
` hemophilia A or B, including long acting prophylaxis
`
`• Novel non-replacement therapies that improve hemostasis.
`
`Chronic inflammatory and autoimmune disorders
`
`• Innovative protein/antibody therapies
`• Targets focusing on:
`
`• Surface molecules on cells involved in immune regulation
`
`• Cytokines and chemokines.
`
`Protein technologies
`
` • Formulation
` • Expression and production
` • Engineering and modifications
` • Manufacturing.
`
`Protein drug delivery systems (formulations and devices)
`
` • Injection, infusion
` • Sustained release
` • Oral, nasal, transdermal.
`
`Partnering October 2008 / www.novonordisk.com/science/partnering
`
`Novo Nordisk Exhibit 2533
`Mylan Pharms. Inc. v. Novo Nordisk A/S
`IPR2023-00724
`Page 00003
`
`
`
`Contacts
`
`
`Diabetes
`Finn Benned Hansen, Corp. VP, e-mail: fbh@novonordisk.com
`
`
`
`Diabetes, devices and delivery systems
`Martin E. Judge, Sourcing Director, e-mail: meju@novonordisk.com
`
`Diabetes, formulations and drug delivery technology
`Tomas Landh, Sourcing Director, e-mail: tolh@novonordisk.com
`
`Hemostasis and autoimmunity
`Jørn Roland Müller, Corp. VP, e-mail: jrom@novonordisk.com
`
`Hemostasis and autoimmunity
`Thomas Hanke, Sourcing Director, e-mail: thnk@novonordisk.com
`
`Hemostasis and autoimmunity
`Dan Zekzer, Senior Sourcing Director, e-mail: daze@novonordisk.com
`
`be
`
`Partnering October 2008 / www.novonordisk.com/science/partnering
`
`Novo Nordisk Exhibit 2533
`Mylan Pharms. Inc. v. Novo Nordisk A/S
`IPR2023-00724
`Page 00004
`
`
Accessing this document will incur an additional charge of $.
After purchase, you can access this document again without charge.
Accept $ Charge
Still Working On It
This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.
Give it another minute or two to complete, and then try the refresh button.
A few More Minutes ... Still Working
It can take up to 5 minutes for us to download a document if the court servers are running slowly.
Thank you for your continued patience.
This document could not be displayed.
We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.
Your account does not support viewing this document.
You need a Paid Account to view this document. Click here to change your account type.
Your account does not support viewing this document.
Set your membership
status to view this document.
With a Docket Alarm membership, you'll
get a whole lot more, including:
- Up-to-date information for this case.
- Email alerts whenever there is an update.
- Full text search for other cases.
- Get email alerts whenever a new case matches your search.
One Moment Please
The filing “” is large (MB) and is being downloaded.
Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.
Your document is on its way!
If you do not receive the document in five minutes, contact support at support@docketalarm.com.
Sealed Document
We are unable to display this document, it may be under a court ordered seal.
If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.
Access Government Site
